Content Conference Coverage Conferences EASL 2010
EASL 2010: World Hepatitis Alliance Releases Major Report on Viral Hepatitis Policy at EASL Meeting
- Details
- Category: Hepatitis B
- Created on Tuesday, 20 April 2010 12:55
In conjunction with the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) last week in Vienna, the World Hepatitis Alliance released its first major policy report on viral hepatitis, focusing on hepatitis B and C. Based on research commissioned by the World Health Organization (WHO), the report describes global responses to the urgent public health issue of viral hepatitis, finding that many counties lack national prevention and management policies even though 10 times more people have hepatitis B and C than HIV/AIDS.
EASL 2010: Spontaneous Undetectable Hepatitis B Virus DNA Is Uncommon, especially without HBeAg Clearance
- Details
- Category: HBV Treatment
- Created on Friday, 14 May 2010 19:17
Clearance of hepatitis B virus (HBV) DNA from the blood seldom occurs without treatment even after a decade, researchers reported at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) last month in Vienna. Among people who experience hepatitis B "e" antigen (HBeAg) clearance, however, the likelihood of also achieving undetectable viral load was higher, approaching 50% at 10 years.
EASL 2010: Tenofovir (Viread) Effective for Treatment of Chronic Hepatitis B Patients with Suboptimal Response to Adefovir (Hepsera)
- Details
- Category: HBV Treatment
- Created on Tuesday, 04 May 2010 12:56
Treatment with tenofovir (Viread) monotherapy for up to 96 weeks produced complete suppression of hepatitis B virus (HBV) in patients who had detectable viral load using the related nucleotide analog adefovir (Hepsera), according to data from a pooled analysis presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) last month in Vienna. In addition, tenofovir was well tolerated and no drug resistance was observed.
Longer Treatment with Pegylated Interferon Works Better for Hepatitis B Genotype D
- Details
- Category: HBV Treatment
- Created on Friday, 07 May 2010 12:56
HBeAg negative people with hepatitis B virus (HBV) genotype D doubled their rate of sustained response when treated with pegylated interferon for 2 years instead of 1 year, and HBsAg clearance was also more likely with longer therapy, according to study results presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) last month in Vienna
EASL 2010: HBV DNA and HBsAg Levels Predict Likelihood of Sustained Response to Pegylated Interferon for Hepatitis B
- Details
- Category: HBV Treatment
- Created on Tuesday, 27 April 2010 12:55
Decreases in levels of hepatitis B virus (HBV) DNA and hepatitis B surface antigen (HBsAg) while receiving treatment with pegylated interferon can help predict which hepatitis B "e" antigen (HBeAg) negative patients will ultimately achieve a sustained response, according to presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) this month in Vienna. Investigators recommended that people who do not experience adequate decreases in these levels by week 12 should discontinue therapy.
More Articles...
- EASL 2010: Tenofovir (Viread) Demonstrates High Barrier to Resistance over 3 Years in Chronic Hepatitis B Patients
- EASL 2010: Tenofovir/emtricitabine (Truvada) Prevents Hepatitis B Recurrence after Liver Transplantation in Patients with Mild Kidney Impairment
- EASL 2010: Measurable Neurocognitive Impairment Persists after Episodes of Hepatic Encephalopathy in People with Liver Cirrhosis
- EASL 2010: MARS and Prometheus Artificial Liver Devices Offer Some Benefits for Patients with Liver Failure, but Did Not Improve Survival
- EASL 2010: European Study Finds More than Half of HIV/HCV Coinfected Patients Do Not Receive Treatment despite Advanced Fibrosis
- EASL 2010: PROTECT Study Finds One-third of Liver Transplant Patients Achieve Sustained Response to Pegylated Interferon plus Ribavirin
- EASL 2010: Achillion Announces Additional Promising Data from Phase 1b Trial of HCV Protease Inhibitor ACH-1625
- EASL 2010: HIV/HCV Coinfected Patients with Acute Hepatitis C Are Equally Likely to Achieve Sustained Response with Interferon plus Ribavirin
- Screening for Liver Cancer in HIV/HCV Coinfected People
- Rifaximin Reduces Encephalopathy Recurrence, Improves Quality of Life in People with Liver Cirrhosis
- EASL 2010: HIV and Hepatitis C Virus Coinfection May Increase Death of CD4 T-cells
- EASL 2010: Child-Pugh Score Changes Do Not Predict Liver Failure among HIV/HCV Coinfected Patients during Hepatitis C Treatment
- EASL 2010: Biopsy Study Suggests Liver Disease Does Not Progress Faster in HIV/HCV Coinfected People
Web Design and Development by